MWNA
NVAX icon

Marshall Wace North America’s Novavax NVAX Stock Holding History

Marshall Wace North America’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.41M Sell
11,613
-6,409
-36% -$1.41M 0.01% 683
2021
Q2 		$3.83M Sell
18,022
-26,328
-59% -$4.82M 0.02% 634
2021
Q1 		$8.04M Buy
44,350
+30,625
+223% +$6.1M 0.03% 442
2020
Q4 		$1.53M Buy
+13,725
New +$1.46M 0.01% 821
2013
Q4 		– Sell
-2,095
Closed -$132K – 798
2013
Q3 		$132K Buy
+2,095
New +$118K ﹤0.01% 579

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace North America's NVAX Position: Q3 2021 in Review

Marshall Wace North America reduced its Novavax (NVAX) stake by 36% in Q3 2021, selling an estimated $1.41M and leaving 11,613 shares worth $2.41M. The position accounts for 0.01% of the portfolio, ranked #683.

Marshall Wace North America first reported a position in NVAX in Q3 2013 and has held it in 5 quarters since. The position peaked at $8.04M in Q1 2021. 443 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

  • Marshall Wace North America held 11,613 shares of Novavax worth $2.41M as of Q3 2021.
  • Marshall Wace North America sold 6,409 Novavax shares in Q3 2021, an estimated $1.41M.
  • Novavax made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #683 holding.
  • Marshall Wace North America first reported a position in Novavax in Q3 2013 and has held it in 5 quarters since.
  • Marshall Wace North America's Novavax position peaked at $8.04M in Q1 2021.
  • 443 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.